Mesoporous polydopamine Targeting CDK4/6 Inhibitor toward Brilliant Synergistic Immunotherapy of Breast Cancer
Small · 2024
DOI: 10.1002/smll.202310565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Conglei Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Natural Medicine and Immune Engineering, Henan University, Kaifeng, Henan, 475004, China. Hauptthemen laut MEDLINE: Indoles, Polymers, Breast Neoplasms, Immunotherapy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Joint Fund of Science and Technology R&D Program of Henan Province, Key R&D and Promotion Projects in Henan Province, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Immunotherapy utilizing anti‐PD‐L1 blockade has achieved dramatic success in clinical breast cancer management but is often hampered by the limited immune response. Increasing evidence shows that immunogenic cell death (ICD) recently arises as a promising strategy for enlarging tumor immunogenicity and eliciting systemic anti‐tumor immunity effectively. However, developing simple but versatile, highly efficient but low‐toxic, biosafe, and clinically available transformed ICD inducers remains a huge demand and is highly desirable. Herein, a multifunctional ICD inducer is purposefully developed A6‐MPDA@PAL by integrating photothermal therapy (PTT) nanoplatforms mesoporous polydopamine (MPDA), CDK4/6 inhibitor palbociclib (PAL), and CD44‐specific targeting A6 peptide in a simple way for augmenting the immune antitumor efficacy of anti‐PD‐L1 therapy. Remarkably, the light‐inducible nanoplatforms exhibit multiple favorable therapeutic features ensuring a superior and biosafe PTT/chemotherapy efficacy. Together with stronger accumulative ICD induction, single administration of A6‐MPDA@PAL can trigger robust systemic antitumor immunity and abscopal effect with the assistance of anti‐PD‐L1 blockade by fascinating the intratumoral infiltration of T lymphocytes and reversing the immunosuppressive tumor microenvironment simultaneously, therapy achieving brilliant synergistic immunotherapy with effective tumor ablation. This study presents a simple and smart ICD inducer opening up attractive clinical possibilities for reinforcing the anti‐PD‐L1 therapy against breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Natural Medicine and Immune Engineering, Henan University, Kaifeng, Henan, 475004, China.
- State Key Laboratory of Antiviral Drugs, Henan University, China.
- Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100050, China.
ORCID-Profile: Jianjun Cheng, Jiahua Shi, Guanhua Du
Förderung
- Joint Fund of Science and Technology R&D Program of Henan Province
- Key R&D and Promotion Projects in Henan Province
- China Postdoctoral Science Foundation
- Natural Science Foundation of Henan Province
- Key Scientific Research Program of the Higher Education Institutions of Henan Province
Zitieren
APA
Zhou, C., Zhao, S., Zhang, Y., Cheng, J., Shi, J., & Du, G. (2024). Mesoporous polydopamine Targeting CDK4/6 Inhibitor toward Brilliant Synergistic Immunotherapy of Breast Cancer. Small. https://doi.org/10.1002/smll.202310565
Vancouver
Zhou C, Zhao S, Zhang Y, Cheng J, Shi J, Du G. Mesoporous polydopamine Targeting CDK4/6 Inhibitor toward Brilliant Synergistic Immunotherapy of Breast Cancer. Small. 2024. doi:10.1002/smll.202310565
BibTeX
@article{Zhou2024,
author = {Zhou, Conglei and Zhao, Shuang and Zhang, Yongbo and Cheng, Jianjun and Shi, Jiahua and Du, Guanhua},
title = {Mesoporous polydopamine Targeting CDK4/6 Inhibitor toward Brilliant Synergistic Immunotherapy of Breast Cancer},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202310565}
}
EUVIMED